H.C. Wainwright reiterated a Buy rating and $9 price target on Lineage Cell Therapeutics (LCTX), saying the major breakout event the firm is looking for is visibility out of global partner Roche (RHHBY) regarding OpRegen data and next steps. Monday’s $5M milestone represents yet another tangible piece of evidence for Roche’s progress in the OpRegen program for which they have global rights for dry-AMD and geographic atrophy, the analyst tells investors in a research note. The firm added that data, anecdotes, and comps provide significant support that OpRegen is moving into later studies in Roche’s hands.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LCTX:
- Lineage Therap Secures $5M Milestone Payment
- Lineage Therap Sells 12 Million Shares to Janus
- Positive Buy Rating for Lineage Cell Therapeutics Driven by Clinical Progress and Financial Stability
- Lineage Cell Therapeutics: Progress Amid Financial Challenges
- Lineage Cell Therapeutics Reports Q3 2025 Results